# TGA

Type: organization

Source: AI Intelligence Brief — https://getaibrief.com/entity/tga-organization
Canonical HTML page: https://getaibrief.com/entity/tga-organization

## Timeline

- **2026-02-27**: TGA Approval — Australian regulatory body approves the platform for clinical use in Australia.
- **2023-05**: CE Mark — Virtual Nodule Clinic receives CE marking for expansion into European markets.
- **2022-09**: Series A Funding — Company raises $14M to scale its AI platform globally.
- **2021-03**: FDA Clearance — Optellum receives first-of-its-kind FDA clearance for AI lung cancer decision support.

## Recent coverage (2 stories)

### TGA Launches Review of AI Medical Scribes Over Clinical Manipulation Risks
2026-03-23 01:25:46 · Sentiment: Negative · Impact: 7/10 · Sources: 2

Australia's Therapeutic Goods Administration (TGA) has initiated a formal review of AI-powered clinical documentation tools following concerns over their susceptibility to manipulation. The investigation marks a significant regulatory shift as authorities move to ensure the integrity of AI-generated medical records.
Full story: https://getaibrief.com/story/tga-review-ai-medical-scribes-manipulation

### Optellum Secures TGA Approval for AI Lung Cancer Diagnostic in Australia
2026-02-27 02:36:29 · Sentiment: Positive · Impact: 7/10 · Sources: 3

Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-powered Virtual Nodule Clinic. This milestone allows the company to deploy its lung cancer early-detection technology across the Australian healthcare system, marking a major expansion into the Asia-Pacific market.
Full story: https://getaibrief.com/story/optellum-tga-approval-australia-ai-lung-cancer

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getaibrief.com/guides/methodology for the full editorial methodology.